Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY[R] (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    Business Wire. 2023.